Tempus AI, Inc. (NASDAQ:TEM) is among the many ARK Make investments Inventory Portfolio: Prime 10 Inventory Picks for 2026. On March 3, the corporate introduced a strategic partnership with Merck to fast-track the event of AI-driven precision drugs and assist the pharma-maker’s oncology portfolio and different therapeutic choices.
As a part of the settlement, Merck will leverage Tempus AI, Inc. (NASDAQ:TEM)’s de-identified information and Lens Platform and Workspaces applied sciences to generate new discoveries and speed up the event and efficient use of candidate therapies on a big scale.
In different information, on February 25, JPMorgan analyst Casey Woodring slashed the inventory’s value goal to $60 from $80, with a Impartial ranking, following the corporate’s This fall earnings name a day prior.
Picture from Iovance Biotherapeutics web site
In response to TipRanks, the agency cited Tempus AI, Inc.’s (NASDAQ:TEM) ‘clouded visibility’ on information upside and a revision to its outlook for Ambry as the rationale behind the adjustment.
As of the shut of enterprise on March 4, the inventory is a Reasonable Purchase, with a median upside potential of 52.5%.
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare expertise firm that makes use of synthetic intelligence to advance precision drugs.
Whereas we acknowledge the potential of TEM as an funding, we consider sure AI shares provide larger upside potential and carry much less draw back threat. In case you’re searching for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 40 Most Standard Shares Amongst Hedge Funds Heading Into 2026 and 10 Finest Magic Method Shares for 2026.
Disclosure: None. Comply with Insider Monkey on Google Information.